Examining the Efficacy and Safety of Combined Locoregional Therapy and Immunotherapy in Treating Hepatocellular Carcinoma

被引:2
|
作者
Bajestani, Nojan [1 ]
Wu, Gavin [1 ]
Hussein, Ahmed [1 ]
Makary, Mina S. [2 ]
机构
[1] Ohio State Univ, Coll Med, Columbus, OH 43210 USA
[2] Ohio State Univ, Wexner Med Ctr, Dept Radiol, Div Vasc & Intervent Radiol, 395 W 12th Ave, Columbus, OH 43210 USA
关键词
hepatocellular carcinoma; locoregional therapy; immunotherapy; combination therapy; progression-free survival; overall survival; PERCUTANEOUS RADIOFREQUENCY ABLATION; INTERNAL RADIATION-THERAPY; RANDOMIZED CONTROLLED-TRIAL; TRANSARTERIAL CHEMOEMBOLIZATION; OPEN-LABEL; PHASE-III; SURGICAL RESECTION; MICROWAVE ABLATION; Y-90; MICROSPHERES; SYSTEMIC THERAPY;
D O I
10.3390/biomedicines12071432
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
More than 800,000 people worldwide are diagnosed with HCC (hepatocellular carcinoma) each year, with approximately 700,000 deaths alone occurring in that same year. Treatment of HCC presents complex therapeutic challenges, particularly in intermediate and advanced stages. LRTs such as transarterial chemoembolization (TACE) and ablations have been the mainstay treatment for early to intermediate-stage HCC, and systemic therapies are used to treat intermediate-late-stage HCC. However, novel literature describing combining LRT with systemic therapies has shown promising results. This review explores recent advances in both liver-directed techniques for hepatocellular carcinoma, including bland transarterial embolization, chemoembolization, radioembolization, and ablative therapies in conjunction as well as with systemic therapies, with a focus on combination therapies, patient selection, procedural technique, periprocedural management, and outcomes. Our findings suggest that LRT combined with systemic therapies is a viable strategy for improving progression-free survival and time to progression for patients with intermediate-to-late-stage HCC. However, further investigation is required to refine treatment protocols and define patient cohorts that would benefit the most.
引用
收藏
页数:30
相关论文
共 50 条
  • [21] Bridging locoregional therapy: Longitudinal trends and outcomes in patients with hepatocellular carcinoma
    Oligane, Hayley C.
    Close, Orrie N.
    Xing, Minzhi
    Kim, Hyun S.
    TRANSPLANTATION REVIEWS, 2017, 31 (02) : 136 - 143
  • [22] Systemic therapy with or without locoregional therapy for advanced hepatocellular carcinoma: A systematic review and network meta-analysis
    Ding, Zi-Niu
    Meng, Guang-Xiao
    Xue, Jun-Shuai
    Liu, Hui
    Yang, Long-Shan
    Li, Rui-Zhe
    Mao, Xin-Cheng
    Yan, Yu-Chuan
    Wang, Dong-Xu
    Dong, Zhao-Ru
    Li, Tao
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 184
  • [23] The safety and efficacy of lenvatinib combined with immune checkpoint inhibitors therapy for advanced hepatocellular carcinoma
    Wang, Yun
    Jiang, Man
    Zhu, Jingjuan
    Qu, Jialin
    Qin, Kang
    Zhao, Deze
    Wang, Li
    Dong, Lina
    Zhang, Xiaochun
    BIOMEDICINE & PHARMACOTHERAPY, 2020, 132
  • [24] Efficacy of the Combination of Systemic Sequential Therapy and Locoregional Therapy in the Long-Term Survival of Patients with BCLC Stage C Hepatocellular Carcinoma
    Kawamura, Yusuke
    Akuta, Norio
    Shindoh, Junichi
    Matsumura, Masaru
    Okubo, Satoshi
    Tominaga, Licht
    Fujiyama, Shunichiro
    Hosaka, Tetsuya
    Saitoh, Satoshi
    Sezaki, Hitomi
    Suzuki, Fumitaka
    Suzuki, Yoshiyuki
    Ikeda, Kenji
    Arase, Yasuji
    Hashimoto, Masaji
    Kozuka, Takuyo
    Kumada, Hiromitsu
    CANCERS, 2023, 15 (15)
  • [25] Emerging Opportunities for Combining Locoregional Therapy with Immune Checkpoint Inhibitors in Hepatocellular Carcinoma
    Zeng, Peng
    Shen, Duo
    Zeng, Chu-Hui
    Chang, Xiao-Feng
    Teng, Gao-Jun
    CURRENT ONCOLOGY REPORTS, 2020, 22 (08)
  • [26] Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in unresectable hepatocellular carcinoma: a systematic review and meta-analysis
    Yang, Teng-Kai
    Yu, Ya-Fang
    Tsai, Chiao-Ling
    Li, Hsing-Ju
    Yang, Po-Sheng
    Huang, Kai-Wen
    Cheng, Jason Chia-Hsien
    BMC CANCER, 2022, 22 (01)
  • [27] Outcomes of Post-Immunotherapy Durable Responders of Advanced Hepatocellular Carcinoma- with Emphasis on Locoregional Therapy for Oligoprogression
    Liu, Tsung-Hao
    Chen, San-Chi
    Rau, Kun-Ming
    Lu, Li-Chun
    Lin, Po-Ting
    Su, Yung-Yeh
    Teng, Wei
    Lai, Shiue-Wei
    Yeh, Ren-Hua
    Kao, Tsui-Mai
    Lee, Pei-Chang
    Wu, Chi-Jung
    Chen, Chien-Hung
    Hsu, Chih-Hung
    Lin, Shi-Ming
    Huang, Yi-Hsiang
    Chen, Li-Tzong
    Cheng, Ann-Lii
    Shen, Ying-Chun
    LIVER CANCER, 2024, 13 (05) : 509 - 521
  • [28] Efficacy of Adding Locoregional Therapy in Non-Complete Remission Hepatocellular Carcinoma Treated With Atezolizumab Plus Bevacizumab: A Preliminary Study
    Ishikawa, Toru
    Yamazaki, Shun
    Sato, Ryo
    Jimbo, Ryo
    Kobayashi, Yuji
    Sato, Toshifumi
    Iwanaga, Akito
    Sano, Tomoe
    Yokoyama, Junji
    Honma, Terasu
    ANTICANCER RESEARCH, 2024, 44 (01) : 361 - 368
  • [29] Radiofrequency ablation combined with immunotherapy to treat hepatocellular carcinoma: a comprehensive review
    Xie, Gui-Lin
    Zhong, Zhi-Han
    Ye, Tai-Wei
    Xiao, Zun-Qiang
    BMC SURGERY, 2025, 25 (01)
  • [30] Imaging Assessment of Hepatocellular Carcinoma Response to Locoregional and Systemic Therapy
    Yaghmai, Vahid
    Besa, Cecilia
    Kim, Edward
    Gatlin, Joseph L.
    Siddiqui, Nasir A.
    Taouli, Bachir
    AMERICAN JOURNAL OF ROENTGENOLOGY, 2013, 201 (01) : 80 - 96